Molecular structure of salbutamol
Find information on thousands of medical conditions and prescription drugs.

Volmax

Salbutamol (INN) or albuterol (USAN) is a short-acting β2-adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and COPD. It is marketed by the Allen & Hanbury's respiratory division of GlaxoSmithKline under the trade name Ventolin. The name Albuterol comes from Salbutamol aerosol. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Salbutamol sulfate is usually given by the inhaled route for direct effect on bronchial smooth muscle. This is usually achieved through a metered-dose inhaler (MDI) or nebuliser; but other delivery devices marketed for salbutamol sulfate include the Rotahaler, Diskhaler, and Autohaler. Salbutamol can also be given orally (Volmax®) or intravenously.

Ventolin became available in the United Kingdom in 1969 and in the United States in 1980.

Clinical use

Salbutamol is specifically indicated in the following conditions:

  • acute asthma
  • symptom relief during maintenance therapy of asthma and other conditions with reversible airways obstruction (including COPD)
  • protection against exercise-induced asthma
  • certain conditions involving hyperkalemia

Salbutamol has many bad side effects, including shakiness and tremors.

As a β2-agonist, salbutamol also finds use in obstetrics. Intravenous salbutamol can be used as a tocolytic to relax the uterine smooth muscle to delay premature labour. Whilst preferred over agents such as atosiban and ritodrine, its role has largely been replaced by the calcium-channel blocker nifedipine which is more effective, better tolerated and orally administered. (Rossi, 2004)

Mode of action

As with other β2-adrenergic receptor agonists, salbutamol binds to β2-adrenergic receptors with a higher affinity than β1-receptors. In the airways, activation of β2-receptors results in relaxation of bronchial smooth muscle. resulting in a widening of the airway (bronchodilation). Inhaled salbutamol sulfate has a rapid onset of action, providing relief within 5-15 minutes of administration.

In tocolysis, the activation of β2-receptors results in relaxation of uterine smooth muscle, thus delaying labour.

Adverse effects

Whilst salbutamol is well-tolerated, particularly when compared with previous therapies such as theophylline, like all medications there exists the potential for adverse drug reactions to occur - especially when in high doses, or when taken orally or intravenously.

Common adverse effects include: tremor, palpitations and headache. (Rossi, 2004)

Infrequent adverse effects include: tachycardia, muscle cramps, agitation, hypokalemia, hyperactivity in children, and insomnia. (Rossi, 2004)

Other brand names

Salbutamol is sold under the brand names Airomir, Asmol, Proventil, Sultanol, Ventolin and Volmax.

Read more at Wikipedia.org


[List your site here Free!]


Routine heart disease screening not recommended
From Journal of Family Practice, 5/1/04

US Preventive Services Task Force. Screening for coronary heart disease: Recommendation statement. Ann Intern Med 2004;140:569-572.

* CLINICAL QUESTION

Should high-tech means of screening be used to identify heart disease in asymptomatic individuals?

* BOTTOM LINE

The United States Preventive Services Task Force recommends against routine screening of adults at low risk of heart disease using electrocardiography (ECG), exercise treadmill testing, or computerized tomography (CT) because the harms of screening (additional testing of patients with a false-positive result, labeling of patients with a disease) outweigh the benefits. There is insufficient evidence to support this type of testing even in patients at increased risk. (LOE=2b).

* STUDY DESIGN

Practice guideline

* SETTING

Various (guideline)

* SYNOPSIS

Can screening for disease be harmful, even if the test itself is benign? There are actually many risks associated with screening for disease, which is a hard concept for many patients to grasp, since, after all, if even only one person is found to have the disease, isn't it "worth it"?

The problem with screening occurs not with the people who truly have the disease (of course) but with patients who have a positive test result even though they don't really have the disease (ie, false-positive results). These patients frequently undergo further testing to rule out the disease, may receive unnecessary treatment, and may be labeled as having a disease that they don't have, with all its attendant psychological and financial (ie, life insurance) issues.

There is also a risk of inappropriate reassurance of patients who have the disease but it's not detected by the screening test (ie, false-negative results). So is the case with screening for heart disease. The screening tests often used--a baseline ECG, treadmill testing, or CT--are fairly poor at distinguishing patients who have heart disease from those who don't. In asymptomatic people, ECG changes are present in less than 10% of patients with heart disease. The positive predictive value of exercise stress testing ranges from 6% to 48%, meaning that up to 94% of patients with a positive stress test are not at risk for a cardiovascular event. There are no data evaluating CT testing in asymptomatic patients.

From this information the Task Force concluded that the risks outweigh the benefits in asymptomatic patients. The tests do better in patients at high risk, but there is still significant risk of false-positive results. The Task Force concluded there is insufficient data to support the use of screening in these patients. They suggest relying on the various clinical prediction rules available to estimate heart disease risk, and base management decisions on the results from these rules.

DRUG BRAND NAMES

Albuterol * Airet, Proventil, Ventolin, Volmax Ipratropium * Apo-Ipravent, Atrovent, Kendral-Ipratropium Racemic epinephrine * micoNephrine,Vaponefrin Ribavirin * Copegus, Rebetol, Virazole

COPYRIGHT 2004 Dowden Health Media, Inc.
COPYRIGHT 2004 Gale Group

Return to Volmax
Home Contact Resources Exchange Links ebay